Ling Liu, Chengyi Zhang, Huihui Liu, Huan Luo, Rong Cao, Mingxuan Xiao, Pan Zou, Zhuzhu Xie, Hui Gong, Rui Ma, Miao Yan, Zhichao Jiang
BACKGROUND: Hepatic cancer is a common cancer in clinical practice. Current drug therapies for this condition include targeted therapy, chemotherapy, and immunotherapy. Tumor lysis syndrome (TLS) is the most serious complication of oncology treatment. According to the literature, several cases reported TLS occurred with targeted therapies for hepatic cancer. METHODS: Reporting odds ratio and information component were used to measure the disproportionate signals for TLS associated with targeted therapies, using data from the FDA's Adverse Event Reporting System (FAERS)...
January 30, 2024: Expert Opinion on Drug Safety